Lecture 1 - Control of extracellular calcium homeostasis Flashcards

1
Q

Hypocalcaemia: what is it, what symptoms are present with it, and what signs are medically used to detect it?

A

Low blood calcium levels

Increased nerve excitability - Tetany (spasms), severe forms can cause death by asphyxiation

Chvostek sign
Trousseaus sign

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Chvostek’s sign: what is it?

A

Twitching of facial muscles in response to tapping over the facial nerve

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Trousseaus sign

A

Involuntary contraction of the muscles in the hand and wrist (i.e., carpopedal spasm) that occurs after the compression of the upper arm with a blood pressure cuff

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Hypercalcaemia: what is it and what symptoms are there for it?

A

Too high blood calcium levels

  • Neuromuscular excitability leading to cardiac arrhythmias, lethargy, death
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Calcium stores: what types are their, where are they located, and what percentage of the body’s calcium storage do they contribute to?

A

Insoluble - bones and teeth - 99%
Intracellular soluble - cytosol and nucleus - <0.1%
Intracellular insoluble - Plasma membrane, mitochondria, ER, and other organelles - 0.9%
Extracellular soluble - extracellular fluid - 0.1%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Ca²⁺o homeostasis is maintained by balance of Net Dietary Intake and Urinary Excretion

A

Primary Ca²⁺ regulating endocrine organ is
the Parathyroid Gland

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Parathyroid Hormone (PTH)

A

Produced in Chief cells of Parathyroid gland.
∙ 84 αα hormone but synthesised as:
pre-pro PTH (115 αα)
proPTH (90 αα)
1-84 PTH (t1/2 < 20 mins)

∙ PTH elevates plasma Ca²⁺ levels by:
↑ Bone resorption
↑ Renal Ca²⁺ reabsorption i.e. ↓excretion
(but also ↑Pi excretion)
↑ Production of 1,25(OH)2D3 (Vit D)

∙ PTH secretion is inversely proportional to serum Ca²⁺

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Daily pulsatile PTH secretion

A

Results in mineralised bone formation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Treatment of Post-fracture Osteoporosis

A
  • Teriparatide (Forteo) PTH 1-34
  • Anabolic for bone. ↓ Vertebral & non-vertebral fractures in
    postmenopausal ♀ with osteoporosis.
  • Self-injected (Thigh/Abdomen, requires training)
    s.c. 20 μg/day for 24 months max. £3.5k p.a.
  • Recommended where alendronate / risedronate not tolerated or
    following unsatisfactory response. Contraindicated with
    hypercalcaemia, and small, transient ↑ serum calcium possible.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Vitamin D
1,25(OH)2 vitamin D3

A

Cholesterol
Intestine (Pro-vitamin D3 (7-dehydrocholesterol))
Skin, through UV -> preVitamin D3 - vit d3
Liver (+OH) 25(OH)D3 (Calcifediol) 30ng/ml (constitutive process)
Kidney (+OH) 1,25(OH)2D3 (Calcitriol) 0.03ng/ml (PTH reliance)
The final step is catalysed by 1α- Hydroxylase primarily in the renal Proximal Tubule.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

1,25(OH)2D3

A

1,25(OH)2D3 can ↑ net intestinal Ca²⁺ uptake from 200 to as much as 600 mg / day. It ↑ calbindin expression (D9k and D28k - see later lecture).

1,25(OH)2D3 can also ↑ serum Ca²⁺ levels by
↑ bone resorption and renal Ca²⁺ reabsorption (as for PTH).

Vit D3 (& its –OH derivatives) are lipid soluble → carried in plasma bound to specific globulin VitD binding protein (DBP).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Intestinal Ca²⁺ absorption

A

● 90% of dietary Ca²⁺ absorbed in duodenum, both paracellularly (passive), and, transcellularly (active) requiring 1,25(OH)2D3.

● Very similar in renal DCT except TRPV5 predominant, and calbindin-D28k replaces D9k. Again needs 1,25(OH)2D3.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Vitamin D receptors (VDRs)

A

Activation of nuclear vitamin D receptor (VDR) →
transcriptional regulation of vitamin D-responsive genes.

VDR knockout mice exhibit no abnormalities before
weaning but after weaning exhibit:
* Impaired bone formation
(≡vitamin D-dependent rickets type II)
* Uterine hypoplasia
* Failure to thrive
* Hypocalcaemia
* Growth retardation
* Alopoecia
* Infertility

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Vitamin D sources

A

Dietary Sources – Lipid soluble:
Oily Fish e.g. salmon
Milk (variable)

Ocean - calcium rich environment, organisms in the ocean focus on removing calcium while terrestial focus on gaining calcium (using UVR)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Vitamin D deficiency

A

∙ Rickets – Vitamin D deficiency due to inadequate intake of proVit, or, sun exposure.

Chronic deficiency → 2oHPT, osteomalacia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Ca²⁺o homeostasis involves the integration of effects of 3 calcitropic hormones

A

PTH - resorption/reabsorption
VitD3 - resorption/reabsorption
Calcitonin - decreases resorption (redundant outside of ocean?)

17
Q

PTHRs

A

Parathyroid hormone receptors
* 7-TM protein (GPCR)
* Unusually large ECD
* High expression in bone and kidney
* Mediates endocrine PTH effects and paracrine effects of PTHrP
* Couples to the Gs / AC / cAMP / PKA
pathway - can also stimulate Gq / PLC
pathway with lesser potency / efficacy.

18
Q

The calcium receptor

A

The Calcium Receptor inhibits PTH secretion from the Parathyroid Gland

Clusters of
-ve charge
amino acids:
Ca²⁺ binding?

19
Q

Types of CaRs

A

Type 1 CaR agonists:
∙ Divalent Cations Ca²⁺, Mg²⁺
∙ Spermine
Gd3+
Aminoglycosides (neomycin)

Type 2 CaR “agonists” (positive allosteric modulators)
∙ Calcimimetics: R568, Cinacalcet, Etelcalcitide
∙ Aromatic Amino Acids: L-Trp, L-Phe

CaR “antagonists” (negative allosteric modulators)
Calcilytics: NPS-2143
Acidosis, phosphate

20
Q

Treatments for calcium disorders

A

Calcimimetics: Positive allosteric modulator of the Calcium Receptor - ↓PTH secretion. For treatment of primary & secondary hyperparathyroidism

Calcilytics: Negative allosteric modulator of the Calcium Receptor (or Ca²⁺ antagonist) - ↑ PTH secretion. Proposed use to treat CaR gain-of-function mutations (ADH1)

21
Q

Hyperparathyroidism

A

Secondary to renal failure

Pulling mineral out of bone - ends up in other parts of the body like soft tissues and muscle

22
Q

Extraskeletal calcification

A

Hyperparathyroidism
Calciphylaxis
Although relatively uncommon, calciphylaxis (calcific uremic arterialopathy)
is a complication of extraskeletal calcification and is associated with a high
mortality rate. Lateral view of a leg displaying calciphylaxis and skin necrosis

Cinacalcet (mimpara)

23
Q
A

Elevated PTH levels in renal patients are associated with
increased hospitalisation

24
Q

Calcimimetics

A

Once daily dosing may produce pulsatile PTH secretion changes that help improve bone mass - better than vitamin D which just slowly reduces PTH levels

25
Q

Osteoblasts vs osteoplasts

A

b - build
p - not build

26
Q

Osteoplasts

A

Break down broken parts of bones - allows osteoblasts to come in and replace broken parts